Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
630.00    30.00 (5.00%)
Bid:
626.00
Ask:
634.00
Spread: 8.00 (1.278%)
Market Cap: £762.36m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Director Declaration

27 May 2026 07:00

RNS Number : 7763F
Oxford Biomedica PLC
27 May 2026
 

OXB

Director Declaration

 

Oxford, UK - 27 May 2026OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independent Non-Executive Director has been appointed as a Non-Executive Director of Stevanato Group S.p.A, a NASDAQ listed company with effect from 26 May 2026.

 

-Ends-

 

Enquiries:

OXB:

Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Sarah Elton-Farr / Angela Gray

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNAFMPTMTBTBLF
Date   Source Headline
20th Dec 201711:22 amRNSDirector Dealings / Market Share Purchase
11th Dec 20177:08 amRNSPrimary analysis results from JULIET trial
1st Dec 201710:16 amRNSTotal Voting Rights
23rd Nov 201711:29 amRNSDirector Dealings / Market Share Purchase
9th Nov 20177:00 amRNSOXB to present at Jefferies Healthcare Conference
6th Nov 201712:06 pmRNSHoldings in Company
6th Nov 20177:37 amRNSCTL019 MAA submission to the EMA
1st Nov 20179:19 amRNSTotal Voting Rights
31st Oct 20174:01 pmRNSKymriah submitted to FDA for adults with r/r DLBCL
23rd Oct 201711:27 amRNSDirector Dealings / Market Share Purchase
2nd Oct 201711:21 amRNSTotal Voting Rights
26th Sep 20172:55 pmRNSDirector Dealings / Market Share Purchase
26th Sep 20179:37 amRNSLong Term Incentive Plan Option Grant
25th Sep 20173:05 pmRNSBlock listing application
25th Sep 20179:46 amRNSCantor Fitzgerald Healthcare Conference 2017
22nd Sep 201712:36 pmRNSDirector Dealings
20th Sep 20173:25 pmRNSHolding(s) in Company
19th Sep 20178:58 amRNSDirector Dealings
15th Sep 20179:21 amRNSDirector/PDMR Shareholding
12th Sep 20177:15 amRNSHardman Research: New advanced therapies era
7th Sep 201710:11 amRNSHoldings in Company
5th Sep 201711:45 amRNSDirector/PDMR Shareholding
5th Sep 201711:39 amRNSDirector/PDMR Shareholding
5th Sep 20177:00 amRNSOXB to Present at Rodman & Renshaw Conference
1st Sep 20179:25 amRNSTotal Voting Rights
30th Aug 20174:34 pmRNSCTL019 receives FDA approval
29th Aug 20177:00 amRNSStuart Paynter starts as new CFO
24th Aug 201710:41 amRNSHardman Research: Ready for CTL019 approval
23rd Aug 201710:31 amRNSDirector Dealings / Market Share Purchase
22nd Aug 201710:35 amRNSDirector Dealings / Market Share Sale and Purchase
17th Aug 20177:00 amRNSInterim Results
11th Aug 20177:00 amRNSOXB announces Innovate UK £2m collaboration
7th Aug 20179:05 amRNSHolding(s) in Company
7th Aug 20177:00 amRNSMHRA Licence For Commercial Supply
1st Aug 20179:19 amRNSTotal Voting Rights
25th Jul 20177:00 amRNSNotice of Interim Results
24th Jul 201710:10 amRNSDirector Dealings / Market Share Purchase
18th Jul 20178:47 amRNSDirector Dealings / Market Share Sale and Purchase
14th Jul 20174:49 pmRNSDirector/PDMR Shareholding
14th Jul 20173:30 pmRNSPDMR Shareholding
14th Jul 201711:41 amRNSLTIP for Long Term Incentive Plan
13th Jul 201712:38 pmRNSDirector Dealings / Market Share Sale and Purchase
13th Jul 20177:15 amRNSHoldings in Company
13th Jul 20177:00 amRNSFDA AdCom Recommends CTL019 for Approval
11th Jul 20179:29 amRNSDirector Dealings / Market Share Sale and Purchase
7th Jul 201710:15 amRNSHardman Research: Major deal to supply Novartis
6th Jul 20177:15 amRNSHolding(s) in Company
6th Jul 20177:00 amRNSMajor Commercial and Clinical Supply Agreement
3rd Jul 20172:20 pmRNSTotal Voting Rights
3rd Jul 20172:18 pmRNSBlock Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.